These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 29773493)

  • 21. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
    Beuselinck B; Vano YA; Oudard S; Wolter P; De Smet R; Depoorter L; Teghom C; Karadimou A; Zucman-Rossi J; Debruyne PR; Van Poppel H; Joniau S; Lerut E; Strijbos M; Dumez H; Paridaens R; Van Calster B; Schöffski P
    BJU Int; 2014 Jul; 114(1):81-9. PubMed ID: 24215209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of change in serum C-reactive protein level on the prediction of effects of molecular targeted therapy in patients with metastatic renal cell carcinoma.
    Teishima J; Kobatake K; Kitano H; Nagamatsu H; Sadahide K; Hieda K; Shinmei S; Shoji K; Inoue S; Hayashi T; Inoue Y; Ohara S; Mita K; Matsubara A
    BJU Int; 2016 Jun; 117(6B):E67-74. PubMed ID: 26305535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. C-Reactive Protein Levels and Survival Following Cytoreductive Nephrectomy in 118 Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Study.
    Xu WH; Wang J; Huo DZ; Yin GC; Cao DL; Shi GH; Qu YY; Ye DW; Zhang HL
    Med Sci Monit; 2019 Nov; 25():8984-8994. PubMed ID: 31769434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.
    Klatte T; Fife K; Welsh SJ; Sachdeva M; Armitage JN; 'Aho T; Riddick AC; Matakidou A; Eisen T; Stewart GD
    World J Urol; 2018 Mar; 36(3):417-425. PubMed ID: 29256020
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma.
    Laukhtina E; Pradere B; D Andrea D; Rosiello G; Luzzago S; Pecoraro A; Palumbo C; Knipper S; Karakiewicz PI; Margulis V; Quhal F; Sari Motlagh R; Mostafaei H; Mori K; Kimura S; Enikeev D; Shariat SF
    Urol Oncol; 2020 Dec; 38(12):936.e7-936.e14. PubMed ID: 32962909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.
    Bex A; Mulders P; Jewett M; Wagstaff J; van Thienen JV; Blank CU; van Velthoven R; Del Pilar Laguna M; Wood L; van Melick HHE; Aarts MJ; Lattouf JB; Powles T; de Jong Md PhD IJ; Rottey S; Tombal B; Marreaud S; Collette S; Collette L; Haanen J
    JAMA Oncol; 2019 Feb; 5(2):164-170. PubMed ID: 30543350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
    Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
    Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Jpn J Clin Oncol; 2021 Feb; 51(2):296-304. PubMed ID: 32989464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. C-reactive protein is a predictor of prognosis in renal cell carcinoma patients receiving tyrosine kinase inhibitors: A meta-analysis.
    Wang Z; Peng S; Wang A; Xie H; Guo L; Jiang N; Niu Y
    Clin Chim Acta; 2017 Dec; 475():178-187. PubMed ID: 29080691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study).
    Fiala O; Buti S; Bamias A; Massari F; Pichler R; Maruzzo M; Grande E; De Giorgi U; Molina-Cerrillo J; Seront E; Calabrò F; Myint ZW; Facchini G; Kopp RM; Berardi R; Kucharz J; Vitale MG; Pinto A; Formisano L; Büttner T; Messina C; Monteiro FSM; Battelli N; Kanesvaran R; Büchler T; Kopecký J; Santini D; Giudice GC; Porta C; Santoni M
    Target Oncol; 2024 Jul; 19(4):587-599. PubMed ID: 38704759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.
    Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Davis ID; Azad AA; Wong S; Rosenthal M; Gibbs P; Tran B
    Intern Med J; 2016 Nov; 46(11):1291-1297. PubMed ID: 27507629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preoperative cholesterol level as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with cyto-reductive nephrectomy.
    Lee H; Kim YJ; Hwang EC; Kang SH; Hong SH; Chung J; Kwon TG; Kwak C; Kim HH; Oh JJ; Lee SC; Hong SK; Lee SE; Byun SS;
    BMC Cancer; 2017 May; 17(1):364. PubMed ID: 28545466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry.
    de Groot S; Redekop WK; Sleijfer S; Oosterwijk E; Bex A; Kiemeney LA; Uyl-de Groot CA
    Urology; 2016 Sep; 95():121-7. PubMed ID: 27179773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of novel ACN (albumin, C-reactive protein and neutrophil-to-lymphocyte ratio) prognostication model for patients with metastatic renal cell carcinoma receiving first-line molecular-targeted therapy.
    Tamura K; Ando R; Takahara K; Ito T; Kanao K; Yasui T; Shiroki R; Miyake H
    Urol Oncol; 2021 Jan; 39(1):78.e1-78.e8. PubMed ID: 32958444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab.
    Fukuda S; Saito K; Yasuda Y; Kijima T; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Kageyama Y; Fujii Y
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33602695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early Tumor Shrinkage Under Treatment with First-line Tyrosine Kinase Inhibitors as a Predictor of Overall Survival in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Multi-Institutional Study in Japan.
    Miyake H; Miyazaki A; Imai S; Harada K; Fujisawa M
    Target Oncol; 2016 Apr; 11(2):175-82. PubMed ID: 26341668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy.
    Takagi T; Fukuda H; Kondo T; Ishihara H; Yoshida K; Kobayashi H; Iizuka J; Okumi M; Ishida H; Tanabe K
    Target Oncol; 2019 Apr; 14(2):179-186. PubMed ID: 30927174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.
    Mathieu R; Pignot G; Ingles A; Crepel M; Bigot P; Bernhard JC; Joly F; Guy L; Ravaud A; Azzouzi AR; Gravis G; Chevreau C; Zini L; Lang H; Pfister C; Lechevallier E; Fais PO; Berger J; Vayleux B; Roupret M; Audenet F; Descazeaud A; Rigaud J; Machiels JP; Staehler M; Salomon L; Ferriere JM; Kleinclauss F; Bensalah K; Patard JJ
    Urol Oncol; 2015 Aug; 33(8):339.e9-15. PubMed ID: 26087971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic Value of Baseline Serum C-Reactive Protein Level in Intermediate-Risk Group Patients With Metastatic Renal-Cell Carcinoma Treated by First-Line Vascular Endothelial Growth Factor-Targeted Therapy.
    Takamatsu K; Mizuno R; Omura M; Morita S; Matsumoto K; Shinoda K; Kosaka T; Takeda T; Shinojima T; Kikuchi E; Asanuma H; Oyama M; Mikami S; Oya M
    Clin Genitourin Cancer; 2018 Aug; 16(4):e927-e933. PubMed ID: 29678472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Cytoreductive Nephrectomy on Survival in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy.
    Song Y; Du CX; Zhang W; Sun YK; Yang L; Cui CX; Chi YB; Shou JZ; Zhou AP; Li CL; Ma JH; Wang JW; Sun Y
    Chin Med J (Engl); 2016 Mar; 129(5):530-5. PubMed ID: 26904986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.